This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Reckitt Benckiser faces split trial in 2015 over Gaviscon damages

By Ana Rita Rego ( July 9, 2014, 14:31 GMT | Insight) -- Two UK damages actions against Reckitt Benckiser for delaying the entrance of cheaper versions of popular heartburn drug Gaviscon will be tried in two phases, with dates tentatively set for early May and November 2015. The English High Court will first rule on whether the drug manufacturer is liable to pay “exemplary” damages. The second phase will deal with the bulk of the allegations made by generics makers Teva and Sandoz.Two UK damages actions against Reckitt Benckiser for delaying the entrance of cheaper versions of popular heartburn drug Gaviscon will be tried in two phases, with dates tentatively set for early May and November 2015....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections